GIMBHI’s daily mental health update — 4/30/26

🌮 Zócalo Health raises $15M Series A to scale community-based care for Latino communities (Behavioral Health Business / PR Newswire) — 04/23/26
TL;DR: Kenmore, WA-based Zócalo Health closed a $15M Series A led by EO Ventures (bringing total to $22.75M) to scale its integrated primary care, behavioral health, and community health worker model serving Latino and high-need Medicaid populations across CA, TX, and WA.

🩺 Trayt Health lands $7.17M to expand digital behavioral-primary care coordination platform (Ashleigh Hollowell, Behavioral Health Business) — 04/16/26
TL;DR: Menlo Park-based Trayt Health raised $7.17M (total now $22.7M) to expand its platform coordinating care between behavioral health clinicians and primary care providers, recently launching in Arizona as its 9th state and 20th behavioral health program.

🤖 Sword Health expands AI mental health tool Mind into a full EAP solution (Sword Health Newsroom) — 04/22/26
TL;DR: Sword Health expanded its AI-powered mental health tool Mind into a complete EAP, integrating financial counseling, legal support, manager coaching, and 24/7 crisis intervention into one continuous AI + clinician-supervised platform to replace traditional reactive EAPs.

💊 FDA fast-tracks psychedelic therapies for depression, PTSD, and alcohol use disorder (Heather A. Duerr, Psychiatric Times) — 04/24/26
TL;DR: FDA issued priority vouchers to Compass Pathways, Usona, and Transcend Therapeutics, and cleared noribogaine for alcohol use disorder trials.

🌟 Positive Affect Treatment outperforms standard therapy for anhedonia in major depression (Dennis Thompson, HealthDay/U.S. News) — 04/27/26
TL;DR: SMU’s Alicia Meuret reported in JAMA Network Open that PAT — targeting joy and purpose — outperformed standard treatments for anhedonia, which affects 90% of depression patients.

📊 Gallup finds U.S. depression rate at 19.1%, with 28% of young adults affected (Gallup) — 04/2026
TL;DR: 19.1% of U.S. adults — about 51 million people — currently have or are being treated for depression, with rates among adults under 30 doubling since 2017.

🏛️ KFF launches tracker of Trump administration’s mental health and substance use policy actions (KFF) — 04/28/26
TL;DR: KFF released a policy tracker organizing Trump’s second-term mental health actions across opioids, mental health, federal infrastructure, and gun violence categories.

🏥 Senate bill S.4076 would remove Medicare’s 190-day lifetime cap on inpatient psychiatric care (Psychiatric Times Morning Rounds) — 04/26/26
TL;DR: A bipartisan Senate bill backed by 359 disability and aging organizations would eliminate Medicare’s 1965-era 190-day lifetime limit on inpatient psychiatric coverage.

🧪 EMP-01 shows meaningful improvements for social anxiety disorder in Phase 2a trial (Leah Kuntz, Psychiatric Times) — 04/22/26
TL;DR: EmpathBio’s EMP-01, a next-generation MDMA derivative, demonstrated meaningful symptom improvements for social anxiety disorder in a Phase 2a clinical trial.

🏆 AtaiBeckley and PsyPAN win Silver Award for participant-informed psychedelic research (GlobeNewswire) — 04/27/26
TL;DR: AtaiBeckley received OVID Health’s 2026 Patient Participant Index Silver Award with PsyPAN for integrating clinical trial participant lived experiences into psychedelic mental health research.